Literature DB >> 15355406

Involvement of Fusarium spp. in fungal keratitis.

I Dóczi, T Gyetvai, L Kredics, E Nagy.   

Abstract

Members of the filamentous fungal genus Fusarium are among the agents most frequently causing keratomycosis in humans. Fusarium keratitis is most common among agricultural workers in geographical regions with hot, humid, tropical or semi-tropical climates, but can occur more rarely in countries with temperate climates, such as Hungary. Keratitis is usually treated with a topical antifungal agent, sometimes in combination with sub-conjunctival injections and/or antimycotic agents, but therapeutic keratoplasty may be needed for patients whose corneal infection does not resolve. Early and accurate diagnosis, coupled with appropriate antifungal therapy, is crucial for improving the chances of complete recovery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355406     DOI: 10.1111/j.1469-0691.2004.00909.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  24 in total

1.  Adventitious sporulation in Fusarium keratitis.

Authors:  Philip A Thomas; C A Nelson Jesudasan; P Geraldine; J Kaliamurthy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-30       Impact factor: 3.117

2.  Dermatitis in the Fringe-Toed Lizard, Acanthodactylus nilsoni Rastegar-Pouyani, 1998 (Sauria: Lacertidae) Associated with Fusarium proliferatum.

Authors:  Khosrow Chehri; Nasrullah Rastegar-Pouyani; Farkhondeh Sayyadi
Journal:  Curr Microbiol       Date:  2015-08-21       Impact factor: 2.188

Review 3.  Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.

Authors:  Herman A Carneiro; Jeffrey J Coleman; Alejandro Restrepo; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

4.  Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.

Authors:  Mariana Castanheira; Frederick P Duncanson; Daniel J Diekema; Josep Guarro; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study.

Authors:  Lisa J Keay; Emily W Gower; Alfonso Iovieno; Rafael A Oechsler; Eduardo C Alfonso; Alice Matoba; Kathryn Colby; Sonal S Tuli; Kristin Hammersmith; Dwight Cavanagh; Salena M Lee; John Irvine; R Doyle Stulting; Thomas F Mauger; Oliver D Schein
Journal:  Ophthalmology       Date:  2011-02-04       Impact factor: 12.079

6.  The molecular pathogenicity of Fusarium keratitis: a fungal transcriptional regulator promotes hyphal penetration of the cornea.

Authors:  Xia Hua; Xiaoyong Yuan; Antonio Di Pietro; Kirk R Wilhelmus
Journal:  Cornea       Date:  2010-12       Impact factor: 2.651

7.  Could aflatoxin B1 production by Aspergillus flavus affect the severity of keratitis: an experience in two tertiary health care centers, Egypt.

Authors:  Ghada Ibrahim Ibrahim Barakat; Yasmin Nabiel Kamal; Amira Mohammed Sultan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-22       Impact factor: 3.267

8.  [Successful treatment of Fusarium-associated keratitis with multiresistant pathogen and multimorbid patient].

Authors:  M Alnawaiseh; M R R Böhm; E A Idelevich; K Becker; S Grewe; U H Grenzebach; N Eter
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

9.  Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.

Authors:  Güliz Fatma Yavas; Faruk Oztürk; Tuncay Küsbeci; Zafer Cetinkaya; Sitki Samet Ermis; Nuri Kiraz; Umit Ubeyt Inan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-02       Impact factor: 3.117

Review 10.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.